In 2022, 48.7 million people in the United States (17.3% of the population aged 12 or older), met criteria for substance use disorder (SUD). Nearly 40% of people with opioid
Oct 2025
Relationship between Medicaid coverage design and receipt of medication for alcohol use disorder (MAUD): Probability of receipt increases based on comprehensiveness of plan
Alcohol use disorder (AUD) affects one in ten Americans. As one of the largest payers of AUD treatment in the United States, Medicaid managed care plays a key role in
Oct 2025
Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders
Importance Mental health disorders are prevalent yet undertreated health conditions in the US. Given perceptions about the potential effect of cannabis on individuals with mental health disorders, there is a
Aug 2025
Relationship between Medicaid coverage design and receipt of medication for alcohol use disorder (MAUD): Probability of receipt increases based on comprehensiveness of plan
Alcohol use disorder (AUD) affects one in ten Americans. As one of the largest payers of AUD treatment in the United States, Medicaid managed care plays a key role in
Jun 2025
Pharmacy Market Structure and the Opioid Epidemic
We study how pharmacy competition affects the most severe realizations of the opioid epidemic: overdose deaths. We propose a novel, data-driven market definition where each pharmacy sits at the center
Jun 2025
Medicaid managed care organization service coverage and diagnosis and treatment of opioid use disorder: evidence from quasi-random auto-assignment in Kentucky
Opioid-related mortality continues to claim tens of thousands of American lives annually. Medicaid plays an outsized role in financing opioid use disorder (OUD) treatment, paying for almost 40% of all
Jun 2025
Adolescent Opioid Exposures Before and During the COVID-19 Pandemic
We analyze all reported opioid exposures (n = 13,174) for adolescents aged 12–17 years in the United States, before and during COVID-19 (January 1, 2016–December 31, 2021). Outcome variables measured
Mar 2025
Community pharmacy-based buprenorphine programs and pharmacists’ roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: A systematic review
Buprenorphine is an effective medication for treating opioid use disorder (OUD) and reducing opioid-related overdose deaths. Community pharmacies are key access points for buprenorphine, with pharmacists well-positioned to dispense and counsel patients
Feb 2025
Recreational Cannabis Laws and Fills of Pain Prescriptions in the Privately Insured
Almost half of U.S. states have passed recreational cannabis laws as of May 2024. While considerable evidence to date indicates cannabis may be a substitute for prescription opioids in the
Sep 2024
Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders
Mental health disorders are prevalent yet undertreated health conditions in the US. Given perceptions about the potential effect of cannabis on individuals with mental health disorders, there is a need
